Brii Biosciences Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 2137.HK | ABUS | ASMB | VIR | BHVN | AAPG | |
|---|---|---|---|---|---|---|
| Market cap | 657.07M | 646.06M | 422.38M | 1.80B | 1.78B | 1.53B |
| P/E (TTM) | — | 5.3 | 19.9 | — | — | — |
| Forward P/E | -1.8 | -25.5 | -8.1 | -4.3 | -6.3 | -25.3 |
| Price/book | 0.3 | 3.2 | 1.3 | 1.8 | 145.3 | 18.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −51.07% | −2.26% | −24.72% | +75.49% | −28.34% | −52.70% |
| Today | −0.55% | −2.66% | −2.10% | −1.21% | −0.34% | +2.70% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 2137.HK news ›Brii Biosciences introduces BRiSC platform for dual targeting siRNA drugs
Biotechnology company Brii Biosciences launched its proprietary BRiSC discovery platform to accelerate development of next-generation dual-targeting small interfering RNA therapeutic candidates. Brii Biosciences introduces BRiSC platform…
Brii Biosciences Unveils BRiSC™, an siRNA Therapeutics Discovery Platform
The Manila Times Brii Biosciences Unveils BRiSC™, an siRNA Therapeutics Discovery Platform Proprietary BRiSC™ platform to advance the discovery and development of next-generation dual-targeting siRNA medicines Initial focus on prevalent…
Brii Biosciences Launches to Bring Innovative Medicines to Chinese Patients
- Exclusive agreement with Vir Biotechnology, Inc. grants greater China rights for up to four infectious disease assets - Partnership with Alibaba Group's AliHealth to better identify and educate patients, and better connect them to…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
manilatimes.net2
-
prnewswire.com1
-
vir.com.vn1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.